New drug cocktail aims to fight tough bile duct cancer
NCT ID NCT07152769
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy works better than a standard immunotherapy-plus-chemo regimen for advanced bile duct cancer. About 104 adults with inoperable or metastatic intrahepatic cholangiocarcinoma will be randomly assigned to one of the two treatments. The main goal is to see if the new combo delays cancer growth for at least 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab and tuvonralimab (immunotherapy drugs) plus gemcitabine and cisplatin (chemotherapy)
- What this could lead to
- If successful, this could offer a more effective first-line treatment option for advanced bile duct cancer, potentially slowing disease progression.
- What could go wrong
- This is an early phase 2 study with only 104 participants, so results may not apply to everyone. The new combination may not work better than the existing treatment and could have unknown side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200062, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.